ASIA CHOICES CHampix (Varenicline) Observational Investigation in the CEssation of Smoking

Pfizer

Status: Completed

Conditions: Smoking Cessation

Treatments: Drug: varenicline

Study type: Observational

Funder types: Industry

Identifiers

NCT00808015

A3051112

Details and patient eligibility

About

The purpose of this study is to describe the characteristics of the smoker who wants to quit and his/her treating physician, in addition to determine the safety and effectiveness of Champix in the real-world setting of smokers in routine clinical practice.

Full description

Sampling Method Description: Patients enrolled after being prescribed Champix for smoking cessation at the sole discretion of treating physician and patient.

Enrollment: 1,373 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• All patients enrolled should meet the usual prescribing criteria for Champix® as per the local product information and should be entered into the trial at the investigator's discretion

Exclusion criteria

• All patients enrolled should meet the usual prescribing criteria for Champix® as per the local product information and should be entered into the trial at the investigator's discretion

Trial design

1,373 participants in 1 patient group

Patients in routine practice

Description:

Patients prescribed Champix by treating physician and then entered into trial

Treatment:

Drug: varenicline